Legend Biotech Corp

Stock Chart, Company Information, and Scan Results

$39.60(as of Jul 16, 12:23 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Legend Biotech Corp Company Information, Fundamentals, and Technical Indicators

Stock Price$39.60
Ticker SymbolLEGN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees2,700
CountyUSA
Market Cap$7,258.1M
EBIDTA-228.3M
10-Day Moving Average37.84
P/E Ratio-16.67
20-Day Moving Average36.15
Forward P/E Ratio1,000.00
50-Day Moving Average33.23
Earnings per Share-1.18
200-Day Moving Average36.89
Profit Margin-51.74%
RSI68.12
Shares Outstanding184.0M
ATR1.66
52-Week High60.87
Volume1,954,235
52-Week Low27.34
Most Recent Support Level38.86
Book Value1,017.7M
Most Recent Resistance Level40.78
P/B Ratio3.57
Upper Keltner39.89
P/S Ratio4.99
Lower Keltner32.41
Debt-to-Equity Ratio39.89
Next Earnings Date08/29/2025
Cash Surplus207.3M
Next Ex-Dividend DateUnknown

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Legend Biotech Corp In Our Stock Scanner

example chart graphic
Date: Jul 16, 2025Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Date: Jul 16, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 16, 2025Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 16, 2025Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Date: Jul 16, 2025Scan Name: Long Legged DojiScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.